



(51) International Patent Classification:
A61B 5/0468 (2006.01)

(21) International Application Number:
PCT/AU2013/000970

(22) International Filing Date:
29 August 2013 (29.08.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2012903747 29 August 2012 (29.08.2012) AU

(71) Applicant: UNIVERSITY OF TECHNOLOGY,
SYDNEY [AU/AU]; c/- Level 14, 255 Elizabeth Street,
Sydney, New South Wales 2000 (AU).

(72) Inventor: NGUYEN, Hung; c/- Level 14, 255 Elizabeth
Street, Sydney, New South Wales 2000 (AU).

(74) Agent: DAVIES COLLISON CAVE; Level 14, 255
Elizabeth Street, Sydney, New South Wales 2000 (AU).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: METHOD AND APPARATUS FOR IDENTIFYING HYPERGLYCAEMIA




FIGURE 3

(57) Abstract: A method and apparatus for determining hyperglycaemia. The apparatus includes a sensor and a processor, to determine a QT interval of a patient and any rate of change of the QT interval (dQT/dt), and, output means, to provide an output signal indicative of hyperglycaemia using an algorithm based on the combination of the QT interval and the rate of change of the QT interval. The apparatus may further include further sensor means, to determine a TpTec parameter and the SDNN parameter of a patient, whereby the processor further determines any rate of change of the TpTec parameter ($dTpTec/dt$) and the SDNN parameter to provide an output signal based on any one or combination of the QT interval, the TpTec parameter, the SDNN parameter and the rate of change of these parameters.

METHOD AND APPARATUS FOR IDENTIFYING HYPERGLYCAEMIA

FIELD OF THE INVENTION

[0001] The present invention relates to a method and apparatus for identifying hyperglycaemia, and in particular to a method and apparatus to sense physiological responses of a patient from parameters of an ECG tracing of a patient for early detection of hyperglycaemic conditions.

BACKGROUND OF THE INVENTION

[0002] The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as, an acknowledgement or admission or any form of suggestion that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

[0003] Hyperglycaemia is a condition characterised by abnormally high blood glucose levels. It can lead to ketoacidosis which could be fatal.

[0004] On the other hand, hypoglycaemia is the most common complication experienced by patients with Type 1 diabetes. If not treated properly, severe hypoglycaemia may result in coma and irreversible brain damage.

[0005] For the purpose of detecting various classes of glycaemia, blood glucose levels (BGL) are used. Hypoglycaemia is often considered to be encountered when $BGL \leq 3.33$ mmol/l, normoglycaemia is when $3.33 \text{ mmol/l} < BGL \leq 8.33 \text{ mmol/l}$, and, the hyperglycaemic state is present when $BGL \geq 8.33 \text{ mmol/l}$. Sometimes, hyperglycaemia is defined at different levels, for example $BGL \geq 11.1 \text{ mmol/l}$.

[0006] Conventionally, to determine hypoglycaemic or hyperglycaemic conditions, diabetic patients need to frequently monitor blood glucose level. One conventional technique, for example, requires that the patients draw blood, typically by pricking the finger. The drawn blood is then analysed by a portable device to determine blood glucose levels. The technique can be painful and therefore can significantly discourage the patient from periodically checking blood glucose levels. Obviously, non-invasive techniques would be very desirable.

[0007] Non-invasive methods proposed up to date include systems such as: infrared/near-infrared spectroscopy, iontophoresis, skin conductance, etc. However, none of these have proved sufficiently reliable or unobtrusive.

[0008] The inventor has, fairly recently, invented an effective and sensitive system to monitor hypoglycaemia non-invasively, using physiological parameters such as heart rate, skin impedance and electrocardiogram (ECG). This is disclosed in US Patent No. 7450986, the entire contents of which should be considered to be incorporated in this specification by their reference thereto. As described in US 7450986, ECG offers a quicker, more ubiquitous, non-invasive clinical and research screen for the early detection of hypoglycaemia than other physiological signals.

[0009] In Figure 1 is shown a typical ECG (Electrocardiograph) tracing of a cardiac cycle (heartbeat). The ECG tracing typically consists of a P wave, a QRS complex, and, a T wave.

[0010] The QT interval in particular reflects the duration of the intracellular action potential. It represents the time required for completion of both ventricular depolarisation and repolarisation. Recent studies indicate that insulin resistance affects the activation of the myocardium and can increase the QT interval. Because QT interval is influenced by chronotropic changes, Bazett defined the corrected QT interval (QTc), which is the measure generally used. QTc interval represents an index of myocardial refractoriness and electrical stability and it is associated with ventricular fibrillation and sudden cardiac death.

[0011] Other important ECG parameters include the interval from the peak of the T wave to its end (TpTe) and the associated corrected TpTe (TpTec), and, the standard deviation of the RR interval index (SDNN). The TpTe interval is suggested as a transmural dispersion index of repolarisation. A number of studies show that TpTe interval increases in patients with QT interval prolongation. In addition, the ratio of TpTe interval to QT interval is a potentially significant index for an arrhythmic event. These results imply that TpTe and QT intervals are important parameters contributing to ventricular repolarisation. On the other hand, SDNN is considered to reflect both sympathetic and parasympathetic influence on heart rate variability (HRV).

SUMMARY OF THE INVENTION

[0012] The present invention seeks to provide a non-invasive method and apparatus of identifying hyperglycaemic conditions in patients.

[0013] The present invention also seeks to provide a method and apparatus for detecting hyperglycaemia which is relatively accurate, easy and inexpensive to use.

[0014] The present invention also seeks to provide a hyperglycaemia detection apparatus which may, in a preferred form, trigger an alarm signal within an acceptable time delay from when this condition presents itself, such that appropriate remedial action may be taken in a timely manner.

[0015] In one broad form, the present invention provides a method of determining hyperglycaemia, including the steps of:

sensing a QT interval of a patient;

determining any rate of change of said QT interval; and,

providing an output signal indicative of hyperglycaemia in the event that said rate of change of said QT interval reduces by a predetermined amount.

[0016] Preferably, the method further includes any one or combination of the steps of:

sensing a TpTec interval of a patient; and,

determining any rate of change of said TpTec interval;

whereby, said output signal is provided to indicate hyperglycaemia based on a correlation between said rate of change of each of said QT interval and said TpTec interval.

[0017] Also preferably, the method further includes the steps of:

sensing an RR interval of a patient;

determining the standard deviation of the RR interval (SDNN); and,

said output signal being provided to indicate hyperglycaemia in the event of said standard deviation (SDNN) being above a predetermined value.

[0018] In a further broad form, the present invention provides a method of determining hyperglycaemia, including the steps of:

sensing at least one parameter of heart rate, QT interval, TpTec and SDNN;

determining any rate of change of said parameter(s); and,

providing an output signal in the event of said rate of change of said

-4-

parameter(s) being within a predetermined range.

[0019] In a further broad form, the present invention provides an apparatus for determining hyperglycaemia including:

a sensor;

and a processor, to determine a QT interval of a patient and the rate of change of said QT interval;

output means, to provide an output signal indicative of hyperglycaemia in the event that said rate of change of said QT interval reduces by a predetermined amount.

[0020] Preferably, the apparatus further determines the TpTec parameter of a patient; wherein, said processor further determines any rate of change of said TpTec parameter, and

wherein, said output signal is provided based on a correlation between said rate of change of said QT interval and said TpTec parameter.

[0021] Preferably, the apparatus further determines the SDNN of the RR interval of a patient;

wherein, said processor further determines any rate of change of said SDNN parameter, and

wherein, said output signal is provided based on a correlation between said rate of change of any one or combination of said QT interval, said TpTec parameter, and/or said SDNN parameter.

[0022] In a further broad form, the present invention provides an apparatus for determining hyperglycaemia including:

a sensor, to sense at least one parameter, including heart rate, QT interval, TpTe, and/or SDNN;

a processor, to determine any rate of change of said parameter(s);

output means, to provide an output signal in the event of said rate of change of said parameter(s) being within a predetermined range.

[0023] Preferably, said processor includes a neural network to receive data obtained from said sensor(s), said neural network being programmed with an optimal learning algorithm.

[0024] Also preferably, said neural network is programmed with an optimal Bayesian

-5-

network.

[0025] Also preferably, said output means includes an audio and/or visual alarm.

BRIEF DESCRIPTION OF THE DRAWINGS

[0026] The present invention will become more fully understood from the following detailed description of preferred but non-limiting embodiments thereof, described in connection with the accompanying drawings, wherein:

Figure 1(a) shows an ECG of a normal sinus rhythms, Figure 1(b) shows an ECG of a patient with a high BGL, and Figure 1(c) shows an ECG of a patient with a normal BGL;

Figure 2 shows typical changes in ECG parameters under hyperglycaemic conditions;

Figure 3 shows a flowchart describing the hyperglycaemia detection method/system of the present invention;

Figure 4 shows the blood glucose profiles of five type 1 diabetes (T1D) patients;

Figure 5 shows the evidence framework for Bayesian inference; and

Figure 6 shows how the components may be typically attached to a patient.

DETAILED DESCRIPTION OF THE INVENTION

[0027] As previously described, in Figure 1(a) is shown a typical ECG (Electrocardiograph) tracing of the cardiac cycle (heartbeat).

[0028] The inventor has identified that the onset of a hyperglycaemic condition results in changes to the ECG signal.

[0029] For comparison, Figure 1(b) shows the ECG of a patient having a high blood glucose level (BGL) of 9.81 mmol/l, whilst Figure 1(c) shows the ECG of the patient with a normal BGL of 4.87 mmol/l.

[0030] In particular, the inventor has identified that analysis of the effectiveness of ECG (in particular heart rate, QT interval, TpTe and SDNN) by means of an optimal neural network provides a novel basis for early detection of hyperglycaemia, as well as an indirect measurement of blood glucose levels. There are numerous factors which can affect the accuracy of the device such as environment conditions, stress, and the like. The device

is capable of differentiating between effects caused by environmental conditions and those which initiate the presence of or onset of a particular medical condition.

[0031] The possibility of experimental hyperglycaemia has been shown to shorten QT intervals in both non-diabetic subjects and in those with Type 1 and Type 2 diabetes. It is envisaged that a suitable device may be used for the detection of conditions such as hyperglycaemia, or may be used to provide indirect measurement of blood glucose levels.

[0032] Figure 2 shows typical changes in ECG parameters under hyperglycaemic conditions. In a hyperglycaemic state, an increase in PR is noted, a significant decrease in QTc, RTc, TpTc and SDNN are noted, but no significant changes in HR are noted. The present invention therefore provides a method and apparatus for effectively sensing these parameters, processing these sensed signals and providing an appropriate output, such that appropriate remedial action may be thereby taken.

[0033] Figure 3 shows a flowchart describing the hyperglycaemia detection method/process of the present invention, which provides an output signal based on a correlation of the ECG parameters and their rates of change.

[0034] There are many different ways to implement the signal sensing and signal conditioning for the device. One implementation strategy can be described as follows.

[0035] The ECG may be achieved by placing three Ag-AgCl electrodes in a LeadII configuration on the patient's chest. The signal obtained from the electrodes may then be amplified using an instrumentation amplifier with gain of 10 and CMRR > 100dB at 100Hz. This feeds through a high-pass filter with cutoff frequency of 0.5Hz. A second stage non-inverting amplifier may be added to provide a gain of 100. To obtain a reliable heart rate of the patient, a bandpass filter may be used to detect the QRS complex of the ECG signal. A threshold circuit together with a comparator may be used to reliably detect the R slope. The QT interval, on the other hand is a clinical parameter which can be derived from the ECG signal. Whilst it has been previously identified that during hypoglycaemia, the normalised QTc interval increases, the inventor has now also found that during hyperglycaemia, the normalised QTc interval decreases. QT measurement requires the identification of the start of QRS complex and the end of the T wave. The intersection of the isoelectric line and a tangent to the T wave can be used to measure the QT interval.

[0036] The monitoring for hyperglycaemia and blood glucose level non-invasively is difficult due to imperfections caused by possible conflicting or reinforcing responses from various ECG parameters. This conflicting information is preferably handled in the framework of an optimal Bayesian network in order to obtain accurate determinations from a complex uncertain non-linear physiological system.

[0037] For hyperglycaemia detection using a combination of one or more certain variables (heart rate, QT interval, TpTe, and standard deviation of the RR interval index (SDNN)), a computational intelligence method of analysis is suitable. A Bayesian network is suitable for controlling complex systems. This neuro-estimator may be embedded in an EEPROM of the system to monitor hyperglycaemia episodes in patients. This neural network has a multilayer feedforward neural network structure with one input layer, one hidden layer and one output layer. Essentially, this neural network is trained using a learning algorithm in which synaptic strengths are systematically modified so that the response of the network will increasingly approximate the blood glucose status given by the available qualitative data.

[0038] The inventor has tested responses from five T1D patients, and identified significant changes during the hyperglycaemia phase against the non-hyperglycaemia phase. The actual blood glucose profiles are shown in Figure 4.

[0039] This study shows that associated with hyperglycaemic episodes in 5 T1D patients, their normalised QTc interval reduced significantly (1.0223 ± 0.0748 vs. 0.9892 ± 0.0693 , $P < 0.05$). In addition, their TpTec interval and SDNN also reduced significantly (TpTec: 95.08 ± 9.36 ms vs. 104.87 ± 12.29 ms, $P < 0.0001$, SDNN: 45.5 ± 15.1 ms vs. 74.1 ± 27.9 ms, $P < 0.0001$). On the other hand, their heart rate HR increases, but not significantly (1.0248 ± 0.1187 vs. 1.0726 ± 0.2275 , $P = 0.13$).

[0040] Similar to the above solution, it is also possible to develop a Bayesian network for the classification of hyperglycaemia. In order to detect hyperglycaemic episodes reliably, it is not a simple matter of just using a combination of the above-mentioned parameters: heart rate, QT interval, TpTe and/or SDNN. The main difficulty is different patients have different base values of these parameters. In addition, these base values may vary from day to day.

[0041] False detection may arise from other conditions which could cause similar variations in QTc, TpTe, and/or SDNN. Avoidance of false detection is important if the system is to be relied on by T1D patients.

[0042] The overall data set consisted of a training set and a test set. For these, the whole data set which included both hyperglycaemia data part and non-hyperglycaemia data part were used. For optimal robustness of the evaluation, the framework for Bayesian inference was applied to the training set and it was found that the feedforward neural network architecture with 6 hidden nodes yielded the highest evidence, as shown in Figure 5.

[0043] From the neural network which was derived from the training set with the highest log evidence, estimated blood glucose profiles were found to be correlated significantly to the actual blood glucose values obtained for the test set ($r=0.408$, $P<0.0002$). In addition, the predicted hyperglycaemia classifications in the test set were found to be correlated to the actual hyperglycaemic episodes ($r=0.561$, $P<0.0001$). From the optimal neural network which was derived from the training set, the sensitivity (true positive) value and the specificity (true negative) for the detection of hyperglycaemia ($BG>8.33$ mmol/l) in the test set are 80% and 56% respectively. This has been achieved across various sleep stages.

[0044] Communication between the sensors and the processor may be via a telemetric system, with radio frequency transmitter and receivers at typically 2.4 GHz). Other appropriate communication systems will be apparent to persons skilled in the art.

[0045] The output may be provided in any appropriate format, such as an alarm or other visual or audible output. The alarm may be of any convenient type, and may include a simple radio alarm, a signal transmitted to a monitoring station, or the like.

[0046] The data transmitted from the sensors may either be continuously logged, or monitored at appropriate discrete (short) intervals.

[0047] The system may be typically interfaced with a PC which will continuously log the relevant data using a data management system such as Labview.

[0048] Clearly the invention can vary from that described herein without departing from the scope of the invention. In particular the neural network algorithm needs not be of the type described herein, but any optimal neural network algorithm that is able to provide

substantially real time analysis of multiple data streams in the manner described herein could be used.

[0049] It will therefore be appreciated that the present invention provides a non-invasive method of determining the presence or onset of the hyperglycaemic condition in a person. This method includes, continuously monitoring at least one or more ECG trace parameters of the patient; including, but not limited to heart rate, QTc interval, TpTe interval, and, standard deviation of the RR interval index (SDNN). It then establishes whether one or more of those monitored parameters changes, and if so, the rate of change of that parameter or parameters.

[0050] Data obtained in the first two steps is preferably fed into a neural network programmed with an optimal algorithm. An output signal, such as an alarm signal may be triggered when said neural network establishes conditions which suggest the presence or imminent onset of said hyperglycaemic condition.

[0051] The monitoring of the heart rate, QT interval, TpTe and/or SDNN is preferably done with an ECG. The optimal learning algorithm may be based on a Bayesian neural network.

[0052] The invention extends to apparatus for generating an alarm or other output when a hyperglycaemic condition is present or imminent in a person. The apparatus includes sensors for sensing at one or more of the heart rate, QT interval, TpTe, and SDNN. One or more of the parameters is monitored for change, and, the rate of its change.

[0053] A neural network linked to said sensors may, for example, receive a substantially continuous data stream from said sensors. The neural network is programmed with an optimal learning algorithm and adapted to establish when the sensed parameters, and any change to those parameters, for a particular person are such as to indicate the presence or imminent onset of the physiological condition.

[0054] An alarm or other output linked to said neural network is adapted to be triggered when the presence or imminent onset of said hyperglycaemic condition is established.

[0055] The apparatus may include an optimal Bayesian network.

[0056] The present invention therefore provides a method and apparatus for detecting a reduction in QT interval, monitoring its rate of change (dQT/dt) in a patient, and, if the rate

-10-

of change reduces by a predetermined amount, provides an output signal which indicates a hyperglycaemic condition in the patient.

[0057] The present invention also monitors for change in TpTe parameters, monitors any rate of change ($dTpTe/dt$) and, likewise, is processed to provide a corresponding output signal.

[0058] The present invention also monitors for change in the standard deviation of the RR interval (SDNN), and, likewise is also processed to provide a corresponding output signal.

[0059] All such variations and modifications which become apparent to persons skilled in the art should be considered to fall within the scope of the present invention as broadly hereinbefore described.

The claims defining the present invention are as follows:

1. A method of determining hyperglycaemia, including the steps of:
sensing and determining a QTc interval of a patient;
determining any rate of change of said QTc interval ($dQTc/dt$); and,
providing an output signal indicative of hyperglycaemia based on said QTc interval and said rate of change of said QTc interval.
2. A method of determining hyperglycaemia as claimed in claim 1, further including any one or combination of the steps of:
determining a TpT_{ec} interval of a patient; and
determining any rate of change of said TpT_{ec} interval ($dTpT_{ec}/dt$);
determining the standard deviation of the RR interval (SDNN); and
determining any rate of change of said SDNN interval ($dSDNN/dt$);
said output signal being provided to indicate hyperglycaemia based on any one or combination of said QTc interval, TpT_{ec} interval, and SDNN and/or said rate of change of these said parameters.
3. A method of determining hyperglycaemia, including the steps of:
sensing at least one parameter of heart rate, QTc interval, TpT_{ec} and/or SDNN;
determining any rate of change of said parameter(s); and,
providing an output signal based on any one or combination of these said parameters and their rates of change.
4. An apparatus for determining hyperglycaemia including:
a sensor, to sense a QTc interval of a patient;
a processor, to determine any rate of change of said QTc interval ($dQTc/dt$); and,
output means, to provide an output signal indicative of hyperglycaemia based on the combination of said QTc interval and said rate of change of said QTc interval.
5. An apparatus for determining hyperglycaemia as claimed in claim 4, further

-12-

including:

a sensor to sense a TpTec parameter of a patient;

wherein, said processor further determines any rate of change of said TpTec parameter ($dTpTec/dt$), and

wherein, said output signal is provided based on any one or combination of said QTc interval, TpTec interval and said rate of change of said QT interval and said TpTec parameter.

6. An apparatus for determining hyperglycaemia as claimed in claims 6 or 7, further including:

a sensor to sense an RR interval of a patient;

wherein said processor determines a standard deviation (SDNN) of the RR interval;

and

wherein, said output signal is provided based on any one or combination of said QTc interval, TpTec interval, SDNN and said rate of change of these said parameters.

7. An apparatus for determining hyperglycaemia including:

a sensor, to sense at least one parameter of heart rate, QT interval, TpTe and/or SDNN;

a processor, to determine any rate of change of said parameter(s);

output means, to provide an output signal using any one or combination of said parameters and said rate of change of said parameter(s).

8. An apparatus for determining hyperglycaemia as claimed in any one of claims 5 to 7, wherein

said processor includes a neural network to receive data obtained from said sensor(s), said neural network being programmed with an optimal learning algorithm.


9. An apparatus as claimed in claim 8, wherein


said neural network is programmed with an optimal Bayesian network.

-13-

10. An apparatus as claimed in any one of claim 4 to 10, wherein said output means includes an audio and/or visual alarm.

1/7

ECG of Normal Sinus Rhythm**FIGURE 1(a)**



3/7

Parameters (normalised)	Non-hyperglycaemia (BG<8.33 mmol/l)	Hyperglycaemia (BG≥8.33 mmol/l)	p value
QTc	1.0223 ± 0.0748	0.9892 ± 0.0693	<0.05
HR	1.0248 ± 0.1187	1.0726 ± 0.2275	0.13

FIGURE 2

4/7






FIGURE 3

5/7


**FIGURE 4**

6/7

**FIGURE 5**

7/7

ECG electrodes, ECG amplifier
and transmitter



Embedded processor with receiver
or smart phone

FIGURE 6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU2013/000970

A. CLASSIFICATION OF SUBJECT MATTER A61B 5/0468 (2006.01)		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
EPODOC, WPI, Medline. Keywords: hyperglycaemia, QT, SDNN, TpTe, RR, heart rate, ECG, EKG, HRV, neural network		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	Documents are listed in the continuation of Box C	
☒ Further documents are listed in the continuation of Box C ☒ See patent family annex		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family	
Date of the actual completion of the international search 29 October 2013	Date of mailing of the international search report 29 October 2013	
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA Email address: pct@ipaustalia.gov.au Facsimile No.: +61 2 6283 7999	Authorised officer Dr. Steven Weiss AUSTRALIAN PATENT OFFICE (ISO 9001 Quality Certified Service) Telephone No. 0262832352	

INTERNATIONAL SEARCH REPORT		International application No.
C (Continuation).	DOCUMENTS CONSIDERED TO BE RELEVANT	PCT/AU2013/000970
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 7502644 B2 (GILL et al.) 10 March 2009 abstract, figures 7 and 13, Table I, column 5 line 59 - column 6 line 4, column 11 lines 48 - 51, column 12 lines 34 - 38 and lines 49 - 57, column 15 line 48, column 17 lines 5 - 9, and column 19 lines 50 - 52.	1-5, 7, 10
Y	abstract, figures 7 and 13, Table 1, column 5 line 59 - column 6 line 4, column 11 lines 48 - 51, column 12 lines 34 - 38 and lines 49 - 57, column 15 line 48, column 17 lines 5 - 9, and column 19 lines 50 - 52.	8, 9
X	US 7756572 B1 (FARD et al.) 13 July 2010 Abstract, Figures 7 and 13	1-5, 7, 10
Y	Abstract, Figures 7 and 13	8, 9
X	WO 2006/081336 A2 (PACESETTER, INC.) 03 August 2006 abstract, figures 7 and 13, paragraph [0098] last sentence	1-5, 7, 10
Y	abstract, figures 7 and 13, paragraph [0098] last sentence	8, 9
X	GORDIN, D. et al., 'Acute hyperglycaemia disturbs cardiac repolarization in Type 1 diabetes', Diabetic Medicine, 2007, Vol 25, pages 101-105. Abstract, page 102 Results, Table I, page 103 paragraph 2 last sentence, figure 1(a)	1-4 and 7
X	SANTINI, V. et al., 'QTc and autonomic neuropathy in diabetes: Effects of acute hyperglycaemia and n-3 PUFA', Nutrition, Metabolism & Cardiovascular Diseases, 2007, Vol 17, pages 712-718. Introduction paragraph 2, page 715 column 2 paragraph 4 - page 716 column 1 paragraph 1, figure 1A, figure 4B.	1-4 and 7
X	MARFELLA, R. et al., 'The effect of acute hyperglycaemia on QTc duration in healthy man', Diabetologia, 2000, Vol 43, pages 571-575. Abstract, Figure 2	1-4 and 7
X	MARFELLA, R. et al., 'QTc Dispersion, Hyperglycemia, and Hyperinsulinemia', Circulation, 1999, Vol 100:e149, page 1. Whole Letter	1-4 and 7
X	FIorentini, A. et al., 'The correlation among QTc interval, hyperglycaemia and the impaired autonomic activity', Autonomic Neuroscience: Basic and Clinical, 2010, Vol 154, pages 94-98. Abstract, page 96 section 3.2	1-4, 6 and 7
Y	NGUYEN, H.T. et al., 'Detection of Hypoglycemic Episodes in Children with Type 1 Diabetes using an Optimal Bayesian Neural Network Algorithm', Conference Proceedings of the IEEE Engineering in Medical & Biology Society. 2007 pages 3140-3143. Abstract	8, 9

Form PCT/ISA/210 (fifth sheet) (July 2009)

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/AU2013/000970	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
US 7502644 B2	10 Mar 2009	EP 1850909 B1	07 Apr 2010
		EP 2308555 A2	13 Apr 2011
		EP 2308556 A2	13 Apr 2011
		US 2006167518 A1	27 Jul 2006
		US 7272436 B2	18 Sep 2007
		US 2006167519 A1	27 Jul 2006
		US 7297114 B2	20 Nov 2007
		US 2006167517 A1	27 Jul 2006
		US 7502644 B2	10 Mar 2009
		US 2006167365 A1	27 Jul 2006
		US 7524287 B2	28 Apr 2009
		US 7756572 B1	13 Jul 2010
		US 2009177103 A1	09 Jul 2009
		US 8078271 B2	13 Dec 2011
		US 2009177105 A1	09 Jul 2009
		US 8090435 B2	03 Jan 2012
		US 2009177104 A1	09 Jul 2009
		US 8180441 B2	15 May 2012
		US 2012197149 A1	02 Aug 2012
		WO 2006081336 A2	03 Aug 2006
US 7756572 B1	13 Jul 2010	EP 1850909 B1	07 Apr 2010
		EP 2308555 A2	13 Apr 2011
		EP 2308556 A2	13 Apr 2011
		US 2006167518 A1	27 Jul 2006
		US 7272436 B2	18 Sep 2007
		US 2006167519 A1	27 Jul 2006
		US 7297114 B2	20 Nov 2007
		US 2006167517 A1	27 Jul 2006
		US 7502644 B2	10 Mar 2009
		US 2006167365 A1	27 Jul 2006
		US 7524287 B2	28 Apr 2009
		US 7756572 B1	13 Jul 2010
		US 2009177103 A1	09 Jul 2009
		US 8078271 B2	13 Dec 2011
		US 2009177105 A1	09 Jul 2009

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(July 2009)

INTERNATIONAL SEARCH REPORT Information on patent family members		International application No. PCT/AU2013/000970	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		US 8090435 B2	03 Jan 2012
		US 2009177104 A1	09 Jul 2009
		US 8180441 B2	15 May 2012
		US 2012197149 A1	02 Aug 2012
		WO 2006081336 A2	03 Aug 2006

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/AU2013/000970	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
WO 2006/081336 A2	03 Aug 2006	EP 1850909 B1	07 Apr 2010
		EP 2308555 A2	13 Apr 2011
		EP 2308556 A2	13 Apr 2011
		US 2006167518 A1	27 Jul 2006
		US 7272436 B2	18 Sep 2007
		US 2006167519 A1	27 Jul 2006
		US 7297114 B2	20 Nov 2007
		US 2006167517 A1	27 Jul 2006
		US 7502644 B2	10 Mar 2009
		US 2006167365 A1	27 Jul 2006
		US 7524287 B2	28 Apr 2009
		US 7756572 B1	13 Jul 2010
		US 2009177103 A1	09 Jul 2009
		US 8078271 B2	13 Dec 2011
		US 2009177105 A1	09 Jul 2009
		US 8090435 B2	03 Jan 2012
		US 2009177104 A1	09 Jul 2009
		US 8180441 B2	15 May 2012
		US 2012197149 A1	02 Aug 2012
		WO 2006081336 A2	03 Aug 2006
End of Annex			
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			

专利名称(译)	用于鉴定高血糖的方法和设备		
公开(公告)号	EP2890293A4	公开(公告)日	2016-04-20
申请号	EP2013832488	申请日	2013-08-29
[标]申请(专利权)人(译)	悉尼理工大学		
申请(专利权)人(译)	技术，悉尼大学		
当前申请(专利权)人(译)	悉尼科技大学		
[标]发明人	NGUYEN HUNG		
发明人	NGUYEN, HUNG		
IPC分类号	A61B5/0468 A61B5/00 A61B5/024 A61B5/0245 A61B5/04 A61B5/0456 A61B5/145 G06F19/00		
CPC分类号	A61B5/04012 A61B5/02405 A61B5/0245 A61B5/0456 A61B5/0468 A61B5/14532 A61B5/7267 A61B5/7282 A61B5/7405 A61B5/742 A61B5/746 G16H50/20		
优先权	2012903747 2012-08-29 AU		
其他公开文献	EP2890293A1		
外部链接	Espacenet		

摘要(译)

一种用于确定高血糖的方法和设备。该装置包括传感器和处理器，用于确定患者的QT间期和QT间期的任何变化率 (dQT / dt)，以及输出装置，以使用基于的算法提供指示高血糖的输出信号。QT间期和QT间期变化率的组合。该装置还可以包括另外的传感器装置，以确定患者的TpTec参数和SDNN参数，由此处理器还确定TpTec参数 ($dTpTec / dt$) 和SDNN参数的任何变化率以提供基于输出信号的输出信号。在QT间隔，TpTec参数，SDNN参数和这些参数的变化率中的任何一个或组合上。